Serotonergic pathology and disease burden in the premotor and motor phase of A53T α-synuclein parkinsonism: a cross-sectional study
The Lancet Neurology
Fecha de publicación: June 2019
DOI: https://doi.org/10.1016/S1474-4422(19)30140-1
Autores: Heather Wilson, MSc., George Dervenoulas, MD.,
Gennaro Pagano, PhD., Christos Koros, PhD., Tayyabah Yousaf, MSc
Marina Picillo, MD., et al.
Background: Because of the highly penetrant gene mutation and clinical features consistent with idiopathic Parkinson’s disease, carriers of the autosomal dominant Ala53Thr (A53T; 209G→A) point mutation in the α-synuclein ( SNCA) gene are an ideal population to study the premotor phase and evolution of Parkinson’s pathology.
